Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABOSNASDAQ:INMBNASDAQ:OTLKNASDAQ:VXRT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABOSAcumen Pharmaceuticals$1.05+2.9%$1.05$0.86▼$3.60$63.60M0.09294,093 shs248,147 shsINMBINmune Bio$7.36$7.56$4.32▼$10.50$169.16M1.63334,836 shs287,060 shsOTLKOutlook Therapeutics$1.80+10.4%$1.46$0.87▼$9.25$60.42M0.39765,850 shs1.36 million shsVXRTVaxart$0.47+3.8%$0.40$0.29▼$1.07$106.65M1.272.43 million shs943,272 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABOSAcumen Pharmaceuticals0.00%-1.92%-0.97%-19.05%-68.62%INMBINmune Bio-3.79%-1.34%-6.84%-6.24%-27.49%OTLKOutlook Therapeutics+1.24%0.00%+10.14%+18.12%-79.46%VXRTVaxart-2.36%-1.60%+0.63%-8.63%-45.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABOSAcumen Pharmaceuticals2.281 of 5 stars3.72.00.00.02.01.70.6INMBINmune Bio1.8519 of 5 stars3.60.00.00.02.71.70.6OTLKOutlook Therapeutics1.8511 of 5 stars3.43.00.00.01.90.00.6VXRTVaxart1.9307 of 5 stars3.51.00.00.02.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABOSAcumen Pharmaceuticals 3.33Buy$7.33608.53% UpsideINMBINmune Bio 3.17Buy$22.80206.86% UpsideOTLKOutlook Therapeutics 2.80Moderate Buy$10.20468.25% UpsideVXRTVaxart 3.00Buy$3.00542.40% UpsideCurrent Analyst Ratings BreakdownLatest ABOS, INMB, VXRT, and OTLK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2025OTLKOutlook TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/28/2025ABOSAcumen PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $4.003/28/2025ABOSAcumen PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $11.003/27/2025VXRTVaxartB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$2.50 ➝ $2.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABOSAcumen PharmaceuticalsN/AN/AN/AN/A$4.61 per shareN/AINMBINmune Bio$50K3,415.42N/AN/A$2.07 per share3.59OTLKOutlook TherapeuticsN/AN/AN/AN/A($1.57) per shareN/AVXRTVaxart$47.40M2.25N/AN/A$0.38 per share1.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABOSAcumen Pharmaceuticals-$52.37M-$1.94N/AN/AN/AN/A-32.99%-27.99%8/12/2025 (Estimated)INMBINmune Bio-$30.01M-$1.93N/AN/AN/AN/A-117.48%-78.96%8/7/2025 (Estimated)OTLKOutlook Therapeutics-$75.37M-$0.91N/AN/AN/AN/AN/A-225.12%8/13/2025 (Estimated)VXRTVaxart-$82.46M-$0.27N/AN/AN/A-431.61%-110.46%-62.78%8/14/2025 (Estimated)Latest ABOS, INMB, VXRT, and OTLK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q2 2025OTLKOutlook Therapeutics-$0.55-$0.40+$0.15-$1.50$0.70 millionN/A5/13/2025Q1 2025ABOSAcumen Pharmaceuticals-$0.56-$0.48+$0.08-$0.48N/AN/A5/13/2025Q1 2025VXRTVaxart-$0.07-$0.07N/A-$0.07$2.85 million$20.88 million5/8/2025Q1 2025INMBINmune Bio-$0.43-$0.43N/A-$0.43N/A$0.05 million3/27/2025Q4 2024ABOSAcumen Pharmaceuticals-$0.47-$0.62-$0.15-$0.62N/AN/A3/27/2025Q4 2024INMBINmune Bio-$0.54-$0.40+$0.14-$0.40N/AN/A3/20/2025Q4 2024VXRTVaxart-$0.10-$0.05+$0.05-$0.05$15.68 million$15.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABOSAcumen PharmaceuticalsN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/AVXRTVaxartN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABOSAcumen Pharmaceuticals0.1410.4310.43INMBINmune BioN/A2.592.59OTLKOutlook TherapeuticsN/A0.320.64VXRTVaxartN/A0.830.83Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABOSAcumen Pharmaceuticals71.01%INMBINmune Bio12.72%OTLKOutlook Therapeutics11.20%VXRTVaxart18.05%Insider OwnershipCompanyInsider OwnershipABOSAcumen Pharmaceuticals9.30%INMBINmune Bio35.20%OTLKOutlook Therapeutics4.80%VXRTVaxart2.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABOSAcumen Pharmaceuticals2060.57 million55.81 millionOptionableINMBINmune Bio1022.98 million14.37 millionOptionableOTLKOutlook Therapeutics2033.57 million30.48 millionOptionableVXRTVaxart120228.22 million221.57 millionOptionableABOS, INMB, VXRT, and OTLK HeadlinesRecent News About These CompaniesVaxart to Participate at the Jefferies Global Healthcare Conference on June 5, 2025May 29 at 4:05 PM | globenewswire.comVaxart's Dr. Sean Tucker Calls on Stockholders to Support Reverse Stock Split Proposal by June 1, 2025May 29 at 8:32 AM | quiverquant.comVaxart's Founder and Chief Scientific Officer Provides Video Update to StockholdersMay 29 at 8:00 AM | globenewswire.comVaxart (NASDAQ:VXRT) Stock Crosses Below 200-Day Moving Average - What's Next?May 29 at 5:10 AM | marketbeat.comVaxart Discusses Reverse Stock Split and Capital RaiseMay 28 at 3:41 PM | tipranks.comVaxart Answers Additional Frequently Asked Questions from Retail InvestorsMay 28 at 8:00 AM | globenewswire.comVaxart (NASDAQ:VXRT) vs. Brainstorm Cell Therapeutics (NASDAQ:BCLI) Head to Head ContrastMay 28 at 2:07 AM | americanbankingnews.comVaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 TrialMay 27 at 8:00 AM | globenewswire.comVaxart (NASDAQ:VXRT) Raised to Hold at Wall Street ZenMay 25, 2025 | americanbankingnews.comWall Street Zen Upgrades Vaxart (NASDAQ:VXRT) to "Hold"May 24, 2025 | marketbeat.comVaxart Announces Adjournment of Annual Meeting of StockholdersMay 21, 2025 | globenewswire.comVaxart, Inc. Grants Equity Awards to New CFO Jeroen GrasmanMay 20, 2025 | quiverquant.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | VXRT Stock NewsMay 20, 2025 | gurufocus.comVaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 20, 2025 | globenewswire.comVaxart, Inc. (NASDAQ:VXRT) Insider Steven Lo Acquires 100,000 SharesMay 20, 2025 | insidertrades.comVaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder MeetingMay 16, 2025 | globenewswire.comVaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average - Here's What HappenedMay 16, 2025 | marketbeat.comVaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 TrialMay 15, 2025 | globenewswire.comVaxart Publishes Positive, Complete Data from a Phase 2b Challenge Study of its First-Generation Oral Pill Norovirus Vaccine Candidate in Science Translational MedicineMay 14, 2025 | globenewswire.comVaxart Names Grasman as CFO, Succeeding LeeMay 14, 2025 | marketwatch.comVaxart, Inc. (VXRT) Q1 2025 Earnings Call TranscriptMay 13, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABOS, INMB, VXRT, and OTLK Company DescriptionsAcumen Pharmaceuticals NASDAQ:ABOS$1.05 +0.03 (+2.94%) Closing price 04:00 PM EasternExtended Trading$1.02 -0.03 (-3.24%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.INmune Bio NASDAQ:INMB$7.36 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$7.36 +0.00 (+0.07%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Outlook Therapeutics NASDAQ:OTLK$1.80 +0.17 (+10.43%) Closing price 04:00 PM EasternExtended Trading$1.77 -0.03 (-1.89%) As of 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Vaxart NASDAQ:VXRT$0.47 +0.02 (+3.84%) Closing price 04:00 PM EasternExtended Trading$0.46 -0.01 (-1.78%) As of 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Intel's Loss Is Broadcom's Gain as AVGO Dominates Networking Target's Big Bet: Is It a Cheap Stock or a Value Trap? Dividend Investors Looking for an Edge? 3 Stocks Insiders Bought Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
